Rebecca L. Zur

Rebecca L. Zur

Auto-generated profile, based on publicly available information

Rebecca L. Zur

Department of Obstetrics and Gynecology, McMaster University, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Hamilton Health Sciences

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2024 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
RZRebecca L. Zur
Rebecca L. Zur
KMKelsey McLaughlin
Kelsey McLaughlin
LALaura Aalto
Laura Aalto
YJYidi Jiang
Yidi Jiang
EHElla Huszti
Ella Huszti
JKJohn C. Kingdom
John C. Kingdom
Objective: To identify which components of maternal vascular malperfusion (MVM) pathology are associated with adverse pregnancy outcomes and to investigate the morphological phenotypes of MVM placental pathology and their relationship with distinct clinical presentations of pre‐eclampsia and/or fetal growth restriction (FGR).Design: Retrospective cohort study.Setting: Tertiary care hospital in Toronto, Canada.Population: Pregnant individuals with low circulating maternal placental growth factor (PlGF) levels (<100 pg/mL) and placental pathology analysis between March 2017 and December 2019.Methods: Association between each pathological finding and the outcomes of interest were calculated using the chi‐square test. Cluster analysis and logistic regression was used to identify phenotypic clusters, and their association with adverse pregnancy outcomes. Cluster analysis was performed using the K‐modes unsupervised clustering algorithm.Main outcome measures: Preterm delivery <34+0 weeks of gestation, early onset pre‐eclampsia with delivery <34+0 weeks of gestation, birthweight <10th percentile (small for gestational age, SGA) and stillbirth.Results: The diagnostic features of MVM most strongly associated with delivery <34+0 weeks of gestation were: infarction, accelerated villous maturation, distal villous hypoplasia and decidual vasculopathy. Two dominant phenotypic clusters of MVM pathology were identified. The largest cluster (n = 104) was characterised by both reduced placental mass and hypoxic ischaemic injury (infarction and accelerated villous maturation), and was associated with combined pre‐eclampsia and SGA. The second dominant cluster (n = 59) was characterised by infarction and accelerated villous maturation alone, and was associated with pre‐eclampsia and average birthweight for gestational age.Conclusions: Patients with placental MVM disease are at high risk of pre‐eclampsia and FGR, and distinct pathological findings correlate with different clinical phenotypes, suggestive of distinct subtypes of MVM disease.

25 July 2023 in Research Ethics
Verified
Journal Article
Open access
RZRebecca L Zur
Rebecca L Zur
Pregnancy is a frequently applied exclusion criteria for many forms of research. Common justifications for this exclusion include the potential for teratogenicity, as well as the potential for physiologic changes in pregnancy to impact the research itself. The systematic exclusion of pregnant persons from clinical studies has created a significant gap in knowledge regarding medication safety and efficacy in pregnancy, which continues to cause significant harm to pregnant persons in need of medical therapy. To produce meaningful data and facilitate effective knowledge translation to the clinical setting, special consideration to the pharmacology of pregnancy, as well as to outcomes of concern for this population is essential. The exclusion of pregnant participants from research is not ethically justifiable, as it violates the principles of autonomy, justice and nonmaleficence. While the inclusion of pregnant patients in research presents it’s own challenges, with appropriate methodological, ethical, and clinical considerations, we may be able to narrow the knowledge gap and improve drug availability and safety for pregnant patients and their children.

17 March 2015 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
RZRebecca L. Zur
Rebecca L. Zur
JSJonathan Shapero
Jonathan Shapero
HSHarvey Shapero
Harvey Shapero
Background: Tinea capitis is a common fungal infection of the scalp. If left untreated, tinea capitis infection can cause severe inflammatory reactions and the development of kerion. Tinea capitis is effectively treated with oral antifungals, but at present these are not covered under government assistance programs. Objective: To assess the potential impact of a limited use code for antifungal therapy in the treatment of childhood tinea capitis. Method: Fourteen family physicians practicing in the Jane Finch area were surveyed on their experience treating tinea capitis in this community. Results: Seventy-one percent of surveyed family physicians felt that cost impedes the treatment of tinea capitis in their practice, and 100% felt that a limited use code would have a positive impact on their patients. Conclusion: A limited use code for oral antifungal treatments of tinea capitis may provide a simple, cost-effective solution to a major problem impacting children in the Jane Finch area.

1 March 2021 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
RZRebecca Zur
Rebecca Zur
MCMargaret Casson
Margaret Casson
JBJacqueline Bellaire
Jacqueline Bellaire
MYMark Yudin
Mark Yudin

9 May 2026 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Open access
RZRebecca L. Zur
Rebecca L. Zur
NRNaila Ramji
Naila Ramji
There is strong clinical evidence to support the use of diagnostic Placental Growth Factor (PlGF) testing in the second and third trimesters for early preeclampsia detection, and growing evidence to support its use in the prediction / management of fetal growth restriction. However, as centres across the country move to adopt a national PlGF-testing implementation strategy, there are important bioethical issues to consider. These include individual considerations, relating to the bioethical principles of autonomy, beneficence, non-maleficence, and justice, as well as moral considerations involved in health technology assessment and epistemic bioethical concerns at the systems level. These relate to resource allocation, trade-offs and cost-effectiveness, as well as risk management and practical considerations around informed consent, professional liability, and the physician-patient relationship.

1 September 2024 in Hypertension
Verified
Journal Article
Closed access
COChristopher B. Overgaard
Christopher B. Overgaard
WCWilliam Chan
William Chan
SCSaqib Chowdhary
Saqib Chowdhary
RZRebecca L. Zur
Rebecca L. Zur
RWRodrigo Wainstein
Rodrigo Wainstein
JFJohn S. Floras
John S. Floras
BACKGROUND: Nocturnal hemodialysis (nHD) restores the attenuated brachial artery vasodilator responsiveness of patients receiving conventional intermittent hemodialysis (iHD). Its impact on coronary vasodilatation is unknown. METHODS: We evaluated 25 patients on hemodialysis who fulfilled transplant criteria: 15 on iHD (4-hour sessions, 3 d/wk) and 10 on nHD (≈40 h/wk over 8–10-hour sessions) plus 6 control participants. Following diagnostic angiography, left anterior descending (LAD) coronary flow reserve and mean luminal diameter were quantified at baseline and during sequential intracoronary administration of adenosine (infusion and bolus), nitroglycerin (bolus), acetylcholine (infusion), acetylcholine coinfused with vitamin C, and, finally, sublingual nitroglycerin. RESULTS: Coronary flow reserve in those receiving nHD was augmented relative to iHD (3.28±0.26 versus 2.17±0.12 [mean±SEM]; P <0.03) but attenuated, relative to controls (4.80±0.63; P =0.011). Luminal dilatations induced by intracoronary adenosine and nitroglycerin were similar in nHD and controls but blunted in the iHD cohort ( P <0.05 versus both). ACh elicited vasodilatation in controls but constriction in both dialysis groups (both P <0.05, versus control); vitamin C coinfusion had no effect. Sublingual nitroglycerin increased mid-left anterior descending diameter and reduced mean arterial pressure in controls (+15.2±2.68%; −16.00±1.60%) and in nHD recipients (+14.78±5.46%; −15.82±1.32%); iHD responses were markedly attenuated (+1.9±0.86%; −5.89±1.41%; P <0.05, all comparisons). CONCLUSIONS: Coronary and systemic vasodilator responsiveness to both adenosine and nitroglycerin is augmented in patients receiving nHD relative to those receiving iHD, whereas vasoconstrictor responsiveness to acetylcholine does not differ. By improving coronary conduit and microvascular function, nHD may reduce the cardiovascular risk of patients on dialysis.